MGMT and thymic carcinoma: Interestingly, promoter methylation of the CDKN2A gene was reported in up to 11% of thymomas and 25% of thymic carcinoma [10], while aberrant MGMT methylation and loss of its protein expression was more frequent in thymic carcinoma than in thymoma [11].